Immunophenotype and DNA content of myeloma cells in primary plasma cell leukemia

Shimazaki, Chihiro; Gotoh, Hiroki; Ashihara, Eishi; Oku, Naritoshi; Inaba, Tohru; Murakami, Satoshi; Itoh, Ken; Ura, Yasuaki; Nakagawa, Masao; Fujita, Naohisa

doi:10.1002/ajh.2830390302

Cited by 26 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of immunoglobulin gene revealed the presence of both heavy and K light chain rearrangements, but the TCR-P and bcl-2 genes remained in germ line configuration. Surface markers of leukemic cells analyzed as previously described [2] revealed that CD38 and adhesion molecules such as CDlla, C D l l b , CDllc, CD44 and CD54 were positive. We also evaluated the response of the leukemic cells to various cytokines by the 3H-thymidine uptake method [3].…”

Section: Case Reportmentioning

confidence: 99%

IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon‐α

Yamagata¹,

Shimazaki²,

Goto³

et al. 1994

American J Hematol

Self Cite

View full text Add to dashboard Cite

A 69-year-old woman with IgE/kappa plasma cell leukemia (PCL) was treated with a sequential combination of VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-alpha (IFN alpha). A complete remission was achieved for 14 months. Maintenance therapy with IFN alpha has continued for an additional 10 months. IgE PCL is extremely rare. The biological characteristics of the myeloma cells, including surface marker, adhesion molecule, karyotype, DNA analysis, and the response to various cytokines, are presented.

show abstract

Section: Case Reportmentioning

confidence: 99%

IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon‐α

Yamagata¹,

Shimazaki²,

Goto³

et al. 1994

American J Hematol

Self Cite

View full text Add to dashboard Cite

show abstract

“…3,4,6–8 For example, the loss of the tumor suppressor gene TP53 on chromosome 17p13, is a common event, as it is observed in 50% and 75% of pPCL and sPCL, respectively. 9 Overexpression of MYC genes due to copy number alterations in chromosome 8 is also common, and it distinguishes PCL from MM.…”

Section: Introductionmentioning

confidence: 99%

Clinical Features and Outcomes of Plasma Cell Leukemia: A Single-Institution Experience in the era of Novel Agents

et al. 2012

View full text Add to dashboard Cite

Plasma cell leukemia (PCL) is a rare hematologic malignancy with aggressive clinical and biologic features. Data regarding its prognosis with the use of the novel agents, i.e., the immunomodulatory drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib, are limited. We retrospectively reviewed clinical outcomes, response to therapy, and survival of 17 patients seen at the Penn State Hershey Cancer Institute since the availability of novel agents (2006–2011). Twelve patients had primary PCL (pPCL), and 5 secondary PCL (sPCL). PCL was associated with aggressive clinicobiological features, such as high-risk cytogenetics, elevated serum beta-2-microglobulin and lactate dehydrogenase, International Staging System stage III, and rapid relapse after therapy. With the use of thalidomide, lenalidomide, and bortezomib in 53%, 53%, and 88% patients, respectively, median overall survival (OS) was 18 months in the whole group (95% confidence interval, 11–21 months), and 21 and 4 months in pPCL and sPCL, respectively (P=0.015). OS was inferior to that of 313 consecutive patients with multiple myeloma (MM) treated in the same period, even when compared with a subset of 47 MM with high-risk cytogenetics. Although our data are limited by the small sample size, we conclude that novel agents may modestly improve survival in patients with PCL, when compared to historical controls. Novel therapies do not seem to overcome the negative prognosis of PCL as compared with MM.

show abstract

“…Due to its low incidence, most publications on PCL are based on single case reports. Little is known about the immunophenotype of tumor cells in primary PCL because very few reports have looked at the evaluation of single antigens expression on bone marrow or peripheral blood plasma cells [20][21][22][23][24][25][26][27][28][29].…”

Section: Introductionmentioning

confidence: 99%

Flow cytometric immunophenotypic characteristics of plasma cell leukemia

Kraj¹,

Kopeć-Szlężak²,

Pogłód³

et al. 2011

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:The aim of this prospective study was to define the flow cytometric characteristics of simultaneously investigated bone marrow and peripheral blood plasma cells antigens expression in 36 plasma cell leukemia (PCL) patients. The immunophenotypic profile of plasma cells was determined with a panel of monoclonal antibodies. The antigen expression intensity was calculated as relative fluorescence intensity (RFI). Bone marrow plasma cells showed expression of particular antigens in the following proportion of cases: CD49d 100%, CD29 94%, CD54 93%, CD44 83%, CD56 60%, CD18 26%, CD11b 29%, CD11a 19%, CD117 27%, CD71 30%, CD126 100% and CD19 0%, while the expression of those antigens on peripheral blood plasma cells was present in the following percentage of patients: CD49d 100%, CD29 96%, CD54 93%, CD44 95%, CD56 56%, CD18 50%, CD11b 53%, CD11a 29%, CD117 26%, CD71 28%, CD126 100% and CD19 0%. The expression of CD54 was significantly higher than that of adhesion molecules belonging to the integrin b2 family: CD11a, CD18 and CD11b, on both bone marrow and peripheral blood cells (p < 0.01). Expression of CD18, CD11a and CD11b was differential between two cell compartments: lower on bone marrow and higher on peripheral blood cells. We found that plasma cells in the bone marrow of patients with plasma cell leukaemia showed significantly greater granularity and size than those in the peripheral blood (p = 0.0001 and p = 0.04, respectively). However, no differences in cell size or granularity were revealed between bone marrow plasma cells from patients with PCL and multiple myeloma. In conclusion, impaired expression of adhesion molecules such as CD11a/CD18 (LFA-1) or CD56 may explain hematogenic dissemination characterizing PCL. The following pattern of adhesion molecule expression according to the proportion of plasma cells expressing a given antigen in peripheral blood and bone marrow and arranged in diminishing order may be established: CD49d > CD44 > CD54 > CD29 > CD56 > CD18 > CD11b > CD11a. Immuno-phenotyping of plasma cells in PCL, as in multiple myeloma, might be useful in detecting minimal residual disease in cases with aberrant antigen expression and for selecting therapeutic agents towards specific membrane targets.

show abstract

Immunophenotype and DNA content of myeloma cells in primary plasma cell leukemia

Cited by 26 publications

References 19 publications

IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon‐α

IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon‐α

Clinical Features and Outcomes of Plasma Cell Leukemia: A Single-Institution Experience in the era of Novel Agents

Flow cytometric immunophenotypic characteristics of plasma cell leukemia

Contact Info

Product

Resources

About